Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease

Gut

Volumn 47, Issue 1, 2000, Pages

  Heuschkel, R B ^a,c   MacDonald, T T ^b   Monteleone, G ^b   Bajaj Elliott, M ^b   Smith, J A Walker ^a   Pender, S L F ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Enteral nutrition; Inflammatory bowel disease; Intestine; Matrix metalloproteinase; Tissue inhibitor of metalloproteinase

Indexed keywords

STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CHILD; COLON BIOPSY; COLON CROHN DISEASE; CONTROLLED STUDY; ENTERIC FEEDING; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ULCERATIVE COLITIS;

BLOTTING, WESTERN; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; ENTERAL NUTRITION; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MATRIX METALLOPROTEINASE 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSCRIPTION, GENETIC;

EID: 0033916643     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.1.57     Document Type: Article

References (40)

1. 1 Woessner JFJ. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.
2. 2 Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49:117-37.
3. 3 Salamonsen LA. Matrix metalloproteinases and endometrial remodelling. Cell Biol Int 1994;18:1139-44.
4. 4 Uria JA, Ferrando AA, Velasco G, et al. Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 1994;54:2091-4.
5. 5 Delaisse JM, Eeckhout Y, Sear C, et al. A new synthetic inhibitor of mammalian tissue collagenase inhibits bone resorption in culture. Biochem Biophys Res Commun 1985;133:483-90.
6. 6 Witte MB, Thornton FJ, Kiyama T, et al. Metalloproteinase inhibitors and wound healing: a novel enhancer of wound strength. Surgery 1998;124:464-70.
7. 7 Vaalamo M, Weckroth M, Puolakkainen P, et al. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol 1996;135:52-99.
8. 8 Grant GA, Goldberg GI, Wilhelm SM, et al. Activation of extracellular matrix metalloproteases by proteases and organomercurials. Matrix Suffl 1992;1:217-33.
9. 9 Eeckhout Y, Vaes G, Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J 1977;166:21-31.
10. 10 Eeckhout Y, Vaes G. Proceedings: Activation of the inactive precursor of collagenase by kallikrein and plasmin. Arch Int Physiol Biochim 1974;82:7866.
11. 11 Pender SL, Lionetti P, Murch SH, et al. Proteolytic degradation of intestinal mucosal extracellular matrix after lamina propria T cell activation. Gut 1996;39:284-90.
12. 12 Pender SL, Tickle SP, Docherty AJ, et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-90.
13. 13 Saarialho-Kere UK, Vaalamo M, Puolakkainen P, et al. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996; 148:519-26.
14. 14 Bailey CJ, Hembry RM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994;47:113-16.
15. 15 Beattie RM, Nicholls SW, Domizio P, et al. Endoscopic assessment of the colonic response to corticosteroids in children with UC. J Pediatr Gastroenterol Nutr 1996;22: 373-9.
16. 16 Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol 1991;12:439-47.
17. 17 Monteleone G, MacDonald TT, Wathen NC, et al. Enhancing lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology 1999;117: 1069-77.
18. 18 Tarnuzzer RW, Macauley SP, Farmerie WG, et al. Competitive RNA templates for detection and quantitation of growth factors, cytokines, extracellular matrix components and matrix metalloproteinases by RT-PCR. Biotechniques 1996;20:670-4.
19. 19 Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117:814-22.
20. 20 Gunther U, Matthes H, Herbst H, et al. Phenotype of cells expressing matrix metalloproteinase-3 in ulcerative colitis. Ann N Y Acad Sci 1998;859:237-40.
21. 21 Pender SL, Breese EJ, Gunther U, et al. Suppression of T cell-mediated injury in human gut by interleukin-10: role of matrix metalloproteinases. Gastroenterology 1998;115: 573-83.
22. 22 Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
23. 23 Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989;30:835-8.
24. 24 Yao PM, Maitre B, Delacourt C, et al. Divergent regulation of 92-kDa gelatinase and TIMP-1 by HBECs in response to IL-1beta and TNE-alpha. Am J Physiol 1997;273:L866 74.
25. 25 Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
26. 26 Richards CD, Shoyab M, Brown TJ, et al. Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol 1943;150:5596-603.
27. 27 Roeb E, Graeve L, Mullberg J, et al. TIMP-1 protein expression is stimulated by IL-1 beta and IL-6 in primary rat hepatocytes. FEBS Lett 1994:349:45-9.
28. 28 Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
29. 29 Di Girolamo N, Lloyd A, McCluskey P, et al. Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol 1997;150:653-66.
30. 30 Di Girolamo N, Verma MJ, McCluskey PJ, et al. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res 1996; 15:1060-88.
31. 31 Yoshihara Y, Obata K, Fujimoto N, et al. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995;38:969-75.
32. 32 Roeb E, Purucker E, Breuer B, et al. TIMP expression in toxic and cholestatic liver injury in rat. J Hepalol 1997;27:535-44.
33. 33 Muzzillo DA, Imoto M, Fukuda Y, et al. Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases. J Gastroenterol Hepatol 1993;8: 437-41.
34. 34 Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989;264:17374-88.
35. 35 Leco KJ, Apte SS, Taniguchi GT, et al. Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 1997;401: 213-17.
36. 36 Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998;152: 1005-14.
37. 37 Breese EJ, Michic CA, Kicholls SW, et al.The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease. Aliment Pharmacol Ther 1995;9:547-52.
38. 38 Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029 35.
39. 39 Brennan FM, Browne KA, Green PA, et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997;36:643-50.
40. 40 Pender SL, Fell JM, Chamow SM, et al. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998;160:4098-103.